Muribaculum as a microbial contributor of rifaximin-induced mucosal protection during chemotherapy [PDF]
Gut MicrobesChemotherapy-induced intestinal mucositis is a frequent and dose-limiting toxicity that compromises cancer treatment outcomes and lacks effective targeted interventions.
Carmen Correale +16 more
doaj +2 more sources
Rifaximin Protects Against Inflammation and Fibrosis in MASH: Any Role for Ethanol-Producing Bacteria? [PDF]
PathogensMetabolic Dysfunction-Associated Steato-Hepatitis (MASH) is a multiple-hit disease. Endotoxins, ethanol, and other metabolites of certain gut microbiota can reach the liver and accelerate inflammation and disease progression.
Mohamed Abouelkheir +2 more
doaj +2 more sources
Milk Disposition Kinetics, Residue and Efficacy of Rifaximin After Intramammary Administration in Lactating Cow [PDF]
AntibioticsBackground: Rifaximin is a non-aminoglycoside antibiotic utilized for the treatment of mastitis in cows, but its milk disposition kinetics, residue, and bacteriological status in lactating cow milk have hardly been reported.
Na Yu +6 more
doaj +2 more sources
Lack of association between rifaximin and drug-resistant infections: a global multicenter inpatient cirrhosis cohort [PDF]
Clinical and Molecular HepatologyBackground/Aims Infections with drug-resistant organisms (DROs) are associated with poor outcomes in cirrhosis. Rifaximin, widely used for hepatic encephalopathy (HE), could promote cross-resistance, but data regarding clinical impact are conflicting ...
Jasmohan S. Bajaj +13 more
doaj +2 more sources
Increased risk of antimicrobial resistance in patients with cirrhosis and hepatic encephalopathy using rifaximin [PDF]
Nature CommunicationsRifaximin, a non-absorbable antibiotic used in managing recurrent hepatic encephalopathy (HE), has traditionally been considered low risk for inducing resistance.
Cheng-Hao Kuo +6 more
doaj +2 more sources
Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice
BMC Microbiology, 2023 Background Rifaximin has been increasingly applied in irritable bowel syndrome (IBS) treatment. Whether there were differences in the effects of rifaximin on microbiota from different intestinal segments, especially the small intestine where rifaximin ...
Shengyan Zhang +5 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Non-alcoholic steatohepatitis (NASH) is the progressive stage of non-alcoholic fatty liver disease (NAFLD). The non-absorbable antibiotic rifaximin has been used for treatment of irritable bowel syndrome, traveling diarrhea, and hepatic encephalopathy ...
Jie Jian +9 more
doaj +1 more source
Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS
Hepatology, EarlyView., 2022 The river diagram demonstrates that after transjugular intrahepatic portosystemic shunt insertion (TIPS) the majority of patients without ascites and 50% of the patients with ascites detectable at ultrasound, show the best response in the long term follow‐up.
Alexander Queck +14 more
wiley +1 more source
Hepatology Communications, 2023 Background and Aims:. Hepatic encephalopathy (HE) is associated with significant morbidity and mortality for those with cirrhosis. Despite the known benefits of rifaximin use for HE, treatment retention remains low.
Elizabeth S. Aby +4 more
doaj +1 more source
Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysis. [PDF]
PLoS ONE, 2013 Rifaximin is a semi-synthetic rifamycin derivative that is used to treat different conditions including bacterial diarrhea and hepatic encephalopathy.
Caroline Schrodt +4 more
doaj +1 more source